VMS M&A Wave 2026: Who's Buying and Why It Matters

VMS M&A Wave 2026: Who's Buying and Why It Matters

The vitamins, minerals, and supplements sector is moving fast. Private equity firms and consumer goods giants are acquiring science-backed brands at a pace not seen in years, and the deals being closed in 2026 are telling a very specific story about what buyers actually want. If you operate an independent supplement or nutrition brand, the acquisitions happening right now are your clearest signal yet about what your exit strategy should look like.

The Headline Deals Reshaping the Sector

April 2026 data confirms what industry observers had been anticipating: M&A activity in the VMS space has entered a new gear. Unilever's $1.2 billion acquisition of Gruns stands as the marquee transaction, signaling that legacy consumer goods companies are no longer content to watch science-forward supplement brands grow independently. Danone's purchase of Huel reinforces the same thesis from a nutrition angle.

Smaller but strategically significant deals involving Bioniq, ILS Gummies, and Western Botanicals round out a picture of consolidation that spans personalized nutrition, functional gummies, and botanical formulations. These aren't random bets. Each transaction reflects a deliberate buyer thesis about where the supplement category is heading.

The broader market context supports the urgency. The global supplement industry was approaching $70 billion as of late 2025, with personalization identified as the primary growth vector driving premium valuations. For a deeper look at what's fueling that trajectory, Supplements Near $70B: The Personalization Pivot breaks down the structural forces behind the numbers.

Why Private Equity Is Circling VMS Right Now

Consumer goods giants aren't the only buyers in the room. Private equity has become an increasingly dominant force in VMS acquisitions, and the reasons are straightforward from an investment thesis perspective.

Supplements exhibit what PE firms call defensive growth characteristics. Consumers tend to maintain supplement habits even during economic downturns, subscription models create recurring revenue, and the category benefits from demographic tailwinds as aging populations in the US, UK, Canada, and Australia prioritize preventive health. Combine that with significant fragmentation across sub-segments, and you have a textbook consolidation opportunity.

PE firms are also attracted by the margin profile. A well-positioned supplement brand with proprietary formulations and a loyal direct-to-consumer base can generate EBITDA margins that most physical product categories simply can't match. That financial structure, paired with consolidation upside, makes VMS one of the more compelling roll-up plays available in 2026.

The Three Filters Every Buyer Is Applying

Across the transactions being completed this year, three consistent acquisition criteria have emerged. These aren't hypothetical preferences. They're the actual filters separating brands that receive premium offers from those that get passed over entirely.

Clinical credibility. Buyers are requiring peer-reviewed backing for product claims. This goes beyond regulatory compliance. Acquirers want to see published research, funded studies, or at minimum rigorous third-party testing that validates what the brand is saying about its products. Gruns, for example, built its positioning around formulation transparency and ingredient-level science. That credibility isn't incidental to the $1.2 billion Unilever deal. It's central to it.

Retention-strong customer bases. Acquisition teams are looking hard at cohort retention data, subscription renewal rates, and lifetime value metrics. A brand with 50,000 subscribers renewing at 80% annually is a more attractive asset than a brand generating three times the revenue through one-time purchases with no repeat behavior. Buyers want proof that customers stay, not just that they convert initially.

Defined category leadership. Broad positioning is a liability in the current M&A environment. Buyers are targeting brands that own a specific sub-segment, whether that's personalized micronutrient protocols, condition-specific botanical blends, or age-targeted gummy formats. Bioniq's acquisition reflects this clearly. The brand didn't try to compete across every supplement category. It built a defensible position in blood-biomarker-driven personalization and held it.

Revenue Alone No Longer Qualifies a Brand for a Premium Exit

This is the part that operators need to hear directly: top-line size is no longer sufficient. Brands generating $20 million, $30 million, or more in annual revenue are being passed over if they can't demonstrate clinical credibility or show defensible category ownership.

The market has matured past the point where scale alone commands a premium. Buyers have watched enough supplement brands grow quickly on marketing spend and trend-chasing only to see retention collapse and brand equity erode. They're not paying acquisition multiples for that risk profile anymore.

What they will pay for is a smaller brand with validated science, strong cohort data, and a clear identity in a defined niche. That combination is harder to build from scratch than to acquire, which is precisely why it commands a premium. If your brand currently competes on price, volume, and broad appeal, you're not building toward an acquirable asset. You're building a commodity business.

What This Means If You're Operating a Supplement Brand Today

The strategic implication for independent operators is immediate and time-sensitive. The M&A cycle currently underway won't last indefinitely. Buyer appetite for premium VMS assets is strong now, and brands that position themselves correctly over the next 24 to 36 months will be well-placed to participate in the next phase of consolidation.

Here's what that positioning actually requires:

• Invest in clinical validation now. Commission third-party studies, partner with research institutions, or fund ingredient-level trials that generate publishable data. This isn't a two-month project. It's a 12 to 24 month investment that fundamentally changes how your brand is valued.
• Build retention infrastructure, not just acquisition funnels. Subscription models, loyalty programs, community engagement, and personalized reorder experiences all feed the cohort data that acquirers scrutinize. Your retention curve is a valuation input.
• Narrow your positioning. If you're in seven supplement categories, you don't own any of them. Identify the sub-segment where you have the strongest formulation, the most credible story, and the most loyal customers. Build everything around that position.
• Document your science systematically. Research backing, third-party certifications, formulation rationale, and ingredient sourcing transparency all need to be organized and accessible. Acquirers will conduct deep due diligence, and brands that can't produce that documentation cleanly will lose credibility in the process.

The parallel to what's happening in other wellness verticals is worth noting. The athleisure sector is experiencing its own consolidation dynamic driven by similar forces. Athleisure at $456B: Who's Winning in 2026? explores how brand differentiation and category ownership are separating acquisition targets from commodity players there as well.

The Science Credibility Gap Is the Real Risk

For most independent supplement brands, the largest gap between their current state and acquisition readiness isn't revenue. It's clinical credibility. The supplement industry spent years operating in a space where marketing claims faced minimal scrutiny. That environment produced enormous growth but also enormous liability.

Buyers in 2026 are acutely aware of the regulatory and reputational risk that comes with acquiring a brand built on unsubstantiated claims. The Federal Trade Commission's increased scrutiny of supplement marketing in the US, combined with similar enforcement trends in the UK and Australia, has made acquirers more conservative about clinical documentation requirements. A brand without defensible science isn't just less attractive. It's a legal liability.

This matters even at the product formulation level. Brands that incorporate ingredients with strong research profiles, such as those tied to outcomes in areas like muscle function, cognitive performance, or metabolic health, are better positioned than brands built around trend-driven ingredients with minimal backing. The science has to be real and it has to be documented.

Building Toward an Exit, Not Just Building Revenue

The VMS M&A wave of 2026 is clarifying something that many supplement brand operators have been slow to internalize: there's a meaningful difference between building a supplement business and building an acquirable supplement asset. Revenue is necessary but not sufficient. Scale creates options but not value in isolation.

The brands being acquired at premium multiples right now have made deliberate investments in science, retention, and focused positioning. They've treated clinical validation as a strategic asset rather than a regulatory burden. They've built customer relationships that generate durable cohort data rather than transactional one-off purchases.

The wellness industry's broader evolution is pushing in this direction as well. Technology-enabled personalization, as explored in Technogym Partners With Google Cloud on AI Fitness, is creating new expectations for evidence-based product performance across the entire health and wellness space. Supplement brands that align with that expectation will find buyers. Those that don't will find themselves on the wrong side of a widening acquisition gap.

If you're running an independent VMS brand, the window to position yourself correctly is open. The question is whether you're treating it as a strategic priority or a future problem. The deals being done right now suggest that 24 to 36 months from now, that distinction will determine your exit options entirely.